Xenon acquires exclusive worldwide license to Isis’s antisense drug
As part of a collaboration between both the parties, which was signed in 2010, Xenon will now be responsible for all future development and commercialization of XEN701. XEN701
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The Protein Purification Facility will leverage the cGMP compatible stable, non-lytic protein expression platform for expression of complex and challenging proteins, including Fab fragments and other proteins. ExpreS2ion
In exchange, BioLineRx will receive an upfront license fee, along with future development, regulatory and commercialisation milestones together worth approximately $30m in addition to projected sales-based royalties. CTTQ
Covering areas like physical sciences, medical research, advanced materials, pharmaceutical manufacturing and advanced manufacturing, the projects focus on challenges such as developing new treatments for cancer and ensuring